Cetera Investment Advisers
PCRX icon

Cetera Investment Advisers’s Pacira BioSciences PCRX Stock Holding History

Cetera Investment Advisers’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$368K Buy
16,270
+2,911
+22% +$64.7K ﹤0.01% 3804
2025
Q4 		$346K Buy
+13,359
New +$318K ﹤0.01% 3770

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cetera Investment Advisers's PCRX Position: Q1 2026 in Review

Cetera Investment Advisers increased its Pacira BioSciences (PCRX) stake by 22% in Q1 2026, buying an estimated $64.7K and bringing the position to 16,270 shares worth $368K. The position accounts for ﹤0.01% of the portfolio, ranked #3804.

Cetera Investment Advisers first reported a position in PCRX in Q4 2025 and has held it in 2 quarters since. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

  • Cetera Investment Advisers held 16,270 shares of Pacira BioSciences worth $368K as of Q1 2026.
  • Cetera Investment Advisers bought 2,911 Pacira BioSciences shares in Q1 2026, an estimated $64.7K.
  • Pacira BioSciences made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q1 2026, its #3804 holding.
  • Cetera Investment Advisers first reported a position in Pacira BioSciences in Q4 2025 and has held it in 2 quarters since.
  • 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.